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Background: Pulmonary emphysema is characterized by alveolar destruction and persistent inflammation of the
airways. Although IL-17A contributes to many chronic inflammatory diseases, it’s role in the inflammatory response
of elastase-induced emphysema remains unclear.
Methods: In a model of elastase-induced pulmonary emphysema we examined the response of IL-17A-deficient
mice, monitoring airway inflammation, static compliance, lung histology and levels of neutrophil-related chemokine
and pro-inflammatory cytokines in bronchoalveolar lavage (BAL) fluid.
Results: Wild-type mice developed emphysematous changes in the lung tissue on day 21 after elastase treatment,
whereas emphysematous changes were decreased in IL-17A-deficient mice compared to wild-type mice.
Neutrophilia in BAL fluid, seen in elastase-treated wild-type mice, was reduced in elastase-treated IL-17A-deficient
mice on day 4, associated with decreased levels of KC, MIP-2 and IL-1 beta. Elastase-treated wild-type mice showed
increased IL-17A levels as well as increased numbers of IL-17A+ CD4 T cells in the lung in the initial period
following elastase treatment.
Conclusions: These data identify the important contribution of IL-17A in the development of elastase-induced
pulmonary inflammation and emphysema. Targeting IL-17A in emphysema may be a potential therapeutic strategy
for delaying disease progression.
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by progressive alveolar destruction and inflamma-
tion of the airways caused by noxious particles or gases.
The precise mechanisms behind these pathological changes
remain unclear, although oxidative stress, elastinolytic ac-
tivity, and apoptosis of lung parenchymal cells are believed
to contribute to the pathogenesis of the disease [1]. Current
anti-inflammatory therapies are poorly effective in* Correspondence: miyahara@md.okayama-u.ac.jp
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reproduction in any medium, provided the ormaintaining lung function and symptoms in COPD [2],
therefore, new anti-inflammatory therapeutic strategies
are needed.
It has been reported that there are increased numbers
of tertiary lymphoid follicles in the lungs of patients with
COPD [3,4], and that these follicles are organized struc-
tures with a B-cell core, T cells in the periphery, and
dendritic cells capable of antigen presentation [5-7].
Such observations have led to the hypothesis that COPD
has an autoimmune component [8-10].
IL-17 is produced by inflammatory cells and targets
structural cells such as epithelial cells, fibroblasts, and
smooth muscle cells. The IL-17 family comprises six
members (IL-17A to IL-17 F). IL-17A and IL-17 F dis-
play high sequence homology and can be secreted asal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mouse and human cells [11]. These cytokines are produced
by a subset of CD4+ lymphocytes known as T-helper (Th)
17 cells [12] and contribute to the development of auto-
immune disease [13,14]. IL-17A has been shown to induce
the production of chemokines and inflammatory cytokines
such as keratinocyte-derived chemokine (KC), macrophage
inflammatory protein 2 (MIP-2), and IL-1β, that promote
neutrophilic inflammation [15-17].
Recently, IL-17 has been shown to be associated with
the development of lung inflammatory diseases such as
COPD [16,18,19]. Production of IL-17A was increased
in the bronchial submucosa and subepithelium of COPD
patients [18,19]. Airway smooth muscle strips from
COPD patients expressed IL-17RA and responded to
IL-17 by inducing IL-8 production [16]. However,
other studies failed to show any involvement of IL-17
in the development of COPD. Numbers of IL-17A+
cells in the airways of COPD patients were increased
compared to healthy control subjects, but were not
increased compared to smoking control subjects, and
were not associated with increased neutrophilic in-
flammation [20]. Expression of IL-17 receptors in
COPD was not different compared to non-COPD lung
disease [21].
Nonetheless, the role of IL-17A in the pathogenesis of
COPD remains controversial and often has been based on
indirect evidence. To address this question, we instilled
porcine pancreatic elastase (PPE) in the trachea which first
induces lung inflammation and subsequently results in al-
veolar wall destruction [22,23]. These pathological
changes closely mimic those seen in human emphysema.
Here, we investigated the role of IL-17 in the development
of elastase-inducible emphysema using IL-17A-deficient
(IL-17A−/−) mice.
Methods
Animals and treatment
C57BL/6 wild-type (WT) mice were obtained from
Charles River Japan. IL-17A−/− mice were generated
and backcrossed to C57BL/6 mice for 10 generations
[24]. Ten week-old female WT and female IL-17A−/−
mice were used in experiments.
WT and IL-17A−/− mice received 3.5u of PPE (Sigma-
Aldrich, St. Louis, MO, USA) in 30 μl of saline by intra-
tracheal instillation on day 0 after being anesthetized
with isoflurane. As control groups, WT and IL-17A−/−
mice received 30 μl of saline on day 0. To evaluate
emphysematous changes in the lungs, lung function was
measured, and lung histology and morphometric mea-
surements of air space size were assessed 21 days after
PPE administration. On days 2, 4, and 21 after PPE ad-
ministration, lungs were lavaged for analysis of cellular
composition in bronchoalveolar lavage (BAL) fluid.To determine the timing of production of IL-17A in the
airways, WT mice received PPE, and then lung tissue was
taken at different time points (12 hours, 1 day, 2 day,
4 day, and 21 days) after PPE administration, and the
levels of IL-17A in lung homogenates were measured.
To assess the numbers of IL-17A and IFN-γ producing
cells, WT mice received PPE or saline on day 0, and lung
cells were isolated and IL-17A-producing cells were assessed
by flow cytometry on day 2 after PPE administration.
All experiments were performed in accordance with the
National Institutes of Health guidelines. All protocols
were approved by the Institutional Animal Care and Use
Committees of Okayama University (Okayama, Japan).
Determination of static lung compliance (Cst)
21 days after PPE administration, lung function was
measured in tracheostomized mice using a computer-
controlled small-animal ventilator (flexiVent; SCIREQ,
Montreal, Canada) as described previously [25-27]. In
brief, the mice were anesthetized with sodium pentobar-
bital (Kyoritsu Seiyaku, Tokyo, Japan) by intraperitoneal
injection (12.5 mg/kg = 250 μl/mouse). The mice were
tracheostomized with a 5 mm section of metallic tubing
(= 18 G cannula), ventilated at 180 breaths/min with a
tidal volume of 4 ml/kg and positive end-expiratory pres-
sure of 3 cm H2O, and Cst was assessed. All data points
were determined by flexiVent software (version 5.0).
Lung histology and morphometric measurements of air
space size
On day 21 after PPE administration, mice were killed by
intraperitoneal injection of pentobarbital sodium and
lungs were inflated and fixed by intratracheal instillation
of 10% formalin at a constant pressure of 25 cmH2O. The
tissue was then embedded in paraffin and 2-μm thick sec-
tions were stained with hematoxylin and eosin (H&E). Air
space enlargement was quantified by mean linear intercept
(Lm) calculations in 20 randomly selected fields [28].
BAL
On days 2, 4, and 21 after PPE administration, lungs were
lavaged via the tracheal tube with Hanks’ balanced salt so-
lution (2 × 1 ml, 37°C). The volume of the collected BAL
fluid was measured in each sample, and the number of
cells in the BAL fluid was counted. Cytospin slides were
stained and differentiated in a blinded fashion by counting
at least 200 cells under light microscopy [29].
Measurement of cytokines and chemokines
KC, MIP-2 and IL-1β levels in the BAL fluid, and IL-17A
levels in the supernatants of homogenized lungs were
measured by ELISA as previously described [30]. For
preparation of lung homogenates, lung tissue was frozen
at −70°C immediately after euthanasia. Lung tissue was
Figure 1 Static lung compliance (Cst) values on day 21 after
intratrachial instillation of porcine pancreas elastase (PPE) or
saline. The results are expressed as means ± SEM (n=12 in each
group). *p<0.01 compared to WT saline and IL-17A−/− saline. **p<0.05
compared to WT saline and IL-17A−/− saline. #p<0.01 versus WT PPE.
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proteinase inhibitors at a 1:2.5 ratio of weight per volume
(BD Biosciences, San Diego, CA, USA). The specimens
were homogenized and then centrifuged at 15,000 rpm for
15 min. The supernatants were frozen at −70°C until ana-
lysis [30]. All cytokine and chemokine ELISAs were per-
formed according to the manufacturer’s directions (R&D
Systems, Minneapolis, MN, USA). The limits of detection
were 5 pg/ml for IL-17A, 2 pg/ml for KC, 1.5 pg/ml for
MIP-2, and 3 pg/ml for IL-1β.
Flow cytometry
Lung cells were isolated as previously described follow-
ing collagenase digestion [30]. Intracytoplasmic cytokine
staining was performed as previously described [31,32].
Briefly, after purification, cells were stimulated in vitro
with phorbol myristate acetate (Sigma-Aldrich) and
ionomycin (Sigma-Aldrich). Cells were stained for cell
surface markers with PerCP-conjugated anti-CD4 (BD
Biosciences). Then, cells were stained with PE-conjugated
anti-IL-17A (BD Biosciences) or FITC-conjugated anti-
IFN-γ (BD Biosciences), and analyzed on MACS Quant
flow cytometer (Miltenyi Biotec, Auburn, CA, USA) with
FlowJo software (TreeStar, Ashland, OR, USA). The num-
bers of cytokine-producing CD4 T cells per lung were cal-
culated from the percentages of cytokine-producing cells
and the numbers of CD4 T cells isolated from the lung.
Statistical analysis
All results were expressed as the means ± standard error
of the means (SEM). Statistical significance was detected
by using 1-way ANOVA, followed by post-hoc analysis
with the Tukey-Kramer test for comparisons between
multiple groups. As measured values may not be nor-
mally distributed due to the small sample sizes, nonpara-
metric analysis, Mann–Whitney U-test, was used for
comparison of the numbers of cytokine-producing cells.
Significance was assumed at p values of < 0.05.
Results
Development of emphysema is reduced in IL-17A−/−
mice
To elucidate the role of IL-17A in the development of
emphysema, we examined lung function 21 days follow-
ing PPE treatment. Cst values were significantly higher
in PPE-treated WT mice (mean±SEM: 0.106 ± 0.004 ml/
cmH2O) compared with the values in saline-treated WT
mice (0.065 ± 0.003 ml/cmH2O) and IL-17A−/− mice
(0.067 ± 0.005 ml/cmH2O) 21 days after treatment
(Figure 1). PPE-treated IL-17A−/− mice developed only
small increases in Cst (0.084 ± 0.005 ml/cmH2O) above
saline-treated control mice (p <0.05), but the values were
significantly lower than demonstrated in PPE-treated
WT mice (p<0.01).Lung tissue was stained with H&E. No pathological
differences were observed in WT and IL-17A−/− mice
after saline treatment upon microscopic examination
(Figure 2A and B). Intratracheal PPE instillation to WT
mice produced air space enlargements and alveolar wall
destruction (Figure 2C) and these pathological changes
were much less severe in IL-17A−/− mice. As seen in
Figure 2D, the alveolar walls were less severely damaged
in the lungs of IL-17A−/− mice treated with PPE com-
pared to WT mice.
To further characterize the development of emphy-
sema in IL-17A−/− mice, we determined the airspace
enlargement by measuring the mean linear intercept
(Lm) in 20 randomly selected fields from H&E stained
tissue sections. After PPE treatment, Lm values in WT
mice (118.6 ± 13.9 μm) were significantly increased
compared to saline-treated WT mice (35.1 ± 0.9 μm)
and IL-17−/− mice (36.5 ± 1.5 μm) (Figure 2E). The
increases in Lm values were significantly reduced in
IL-17A−/− mice (87.5 ± 7.4 μm) compared to WT mice
21 days after treatment with PPE (Figure 2E). These histo-
logical and physiological evaluations demonstrated that
IL-17A−/− animals were less susceptible to PPE-induced
changes in the lung.
Elastase-induced pulmonary inflammation is reduced in
IL-17A −/− mice
Early onset lung inflammation is thought to be a major
contributor to the development of emphysema [33]. The
severity of the initial inflammation was compared in WT
and IL-17A −/− mice 4 days after PPE treatment. In WT
mice, inflammatory cell recruitment into the airways
Figure 2 Morphometric assessment performed on day 21 after instillation of PPE or saline. Representative photographs of lungs of
WT mice treated with saline (A), IL-17A−/− mice treated with saline (B), WT mice treated with PPE (C), and IL-17A−/− mice treated with PPE
(D) groups. (E) Mean linear intercepts (Lm) values of alveoli. Lm values were obtained as described in Methods. Bar = 200 μm. Data
represent the mean ± SEM (n=12 in each group). *p<0.01 compared to WT saline and IL-17A−/− saline. #p<0.05 versus WT PPE.
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total cell numbers were largely due to increased num-
bers of neutrophils and macrophages in BAL fluid
(Figure 3A). At this early stage, few histological changes
were detected (data not shown). The increases in neu-
trophil numbers were significantly lower in IL-17A−/−
mice compared to WT mice 4 days after PPE treatment
(41.2 ± 5.4 vs 5.2 ±1.1 ×104/ml) (Figure 3A).
We also assessed inflammatory cell population in
BAL fluid 21 days after PPE treatment when emphy-
sematous changes were already established. Numbers
of lymphocytes in PPE-treated WT and IL-17A−/−
mice were higher compared to saline-treated WT and
IL-17A−/− mice (Figure 3B). However, no differenceswere observed between PPE-treated WT mice and
PPE-treated IL-17A−/− mice in cellular composition
at this point in time (Figure 3B).
Cytokine and chemokine levels in BAL fluid
To determine the basis for the altered inflammatory cel-
lular recruitment in the IL-17A−/− mice, we assessed
levels of BAL neutrophil-related chemokines (KC, MIP-2)
and pro-inflammatory cytokine (IL-1β) 4 days after PPE
treatment. KC, MIP-2, and IL-1β levels were all higher in
WT mice treated with PPE compared to mice which
received saline (Figure 4A). Levels of KC, MIP-2, and
IL-1β in BAL fluid of IL-17A−/− mice were signifi-
cantly lower compared to WT mice following PPE
Figure 3 Cellular composition in bronchoalveolar lavage (BAL)
fluid after intratracheal instillation of PPE or saline. BAL fluid
was obtained as described in Methods. Data represent the mean ±
SEM (n=12 in each group). (A) Cellular composition in BAL fluid on
day 4 after intratracheal instillation of PPE or saline. *p<0.01
compared to WT saline and IL-17A−/− saline. #p<0.05 versus WT
PPE. ##p<0.01 versus WT PPE. (B) Cellular composition in BAL fluid
on day 21 after intratracheal instillation of PPE or saline. *p<0.05
compared to WT saline and IL-17A−/− saline.
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genates because it could not be detected in BAL fluid.
Levels of IL-17A in lung homogenate of PPE-treated WT
mice tended to be higher compared to saline-treated WT
mice, but were not significantly different (7.5 ± 0.5 and
5.4 ± 0.4 pg, respectively) (Figure 4B).
We also assessed chemokine and cytokine levels in
BAL fluid on day 21 after PPE or saline treatment. At
this point in time, KC, MIP-2, and IL-1β levels were all
lower than limits of detection. Levels of IL-17A in lung
homogenates of PPE-treated WT mice also were not
higher compared to saline-treated WT mice (7.3 ± 1.0
and 5.3 ± 0.4 pg, respectively) (Figure 4C).Kinetics of IL-17A levels in the lung
To determine the timing of production of IL-17A in
the airways following PPE treatment, we measured the
levels of IL-17A in lung homogenates from WT mice
at different time points. IL-17A levels were signifi-
cantly higher early after PPE, on days 1 and 2 (10.5 ±
0.7 and 9.8 ± 0.7 pg, respectively) compared to base-
line (day 0) and 12 hours (4.8 ± 0.3 and 5.1 ± 0.4 pg,
respectively) after PPE treatment (Figure 5). The levels
of IL-17A on days 4 or 21 (7.6 ± 0.4 and 7.6 ± 1.1 pg,
respectively) following PPE treatment were not signifi-
cantly higher than levels at baseline (day 0).
Numbers of Th17 cells in the lung
We next determined the numbers of IL-17 produ-
cing cells in the lungs of WT mice, 2 days following
elastase treatment. Previous studies have shown that
Th1 cells contribute to the pathogenesis of COPD,
therefore, we also determined IFN-γ producing cells
[34,35]. Figure 6A shows the representative figures
of percentages of IL-17A+ and IFN-γ+ CD4 T cells
in the lung. IL-17A was detected in 4.78% of lung
CD4 T cells following PPE treatment (4.57% for IL-17A+
IFN-γ-, 0.21% for IL-17A+ IFN-γ+), whereas it was
detected in 2.07% (1.72% for IL-17A+ IFN-γ-, 0.35% for
IL-17A+ IFN-γ+) following saline treatment. Figure 6B
summarizes the numbers of cytokine-producing cells in
the lungs from WT mice. The numbers of IL-17A+ CD4
T cells following PPE treatment were significantly higher
compared to those following saline treatment (23.3 ± 4.0
vs 10.7 ± 2.2 ×104, p<0.05), whereas the numbers of
IFN-γ + CD4 T cells were not different between saline-
treated WT mice and PPE-treated WT mice (40.4 ±
9.1 and 31.8 ± 9.3 ×104, respectively). We assessed the
cellular composition in BAL fluid of WT mice and
IL-17A−/− mice on day 2 after PPE treatment. At this
early stage, the numbers of neutrophils were signifi-
cantly lower in IL-17A−/− mice compared to WT mice
(attached file). These data suggest that elastase increases
numbers of Th17 cells and secretion of IL-17A in the
lungs, and this contributes to acute neutrophilic airway in-
flammation, and subsequently results in emphysematous
changes in the airways.
Discussion
It has been reported that Th17 cells are a critical com-
ponent of the adaptive immune response and IL-17 has
been implicated in chronic inflammatory and auto-
immune diseases [13,14]. There has been much interest
in the role of the adaptive immune response in COPD
since COPD in humans is associated with the develop-
ment of lymphoid follicles in the lung [3,4]. Moreover,
patients with COPD have evidence of anti-elastin anti-
bodies and Th1 responses, suggesting an autoimmune
Figure 4 Cytokine and chemokine levels in the BAL fluid and lung homogenates. (A) KC, MIP-2, and IL-1β levels in BAL fluid. BAL fluid was
obtained from the same groups as described in Figure 3A. Data represent the mean ± SEM (n=12 in each group). *p<0.01 compared to WT
saline and IL-17A−/− saline. #p<0.05 versus WT PPE. ##p<0.01 versus WT PPE. (B) IL-17A levels in lung homogenates on day 4 after intratracheal
instillation of PPE or saline. Data represent the mean ± SEM (n=8 in each group). (C) IL-17A levels in lung homogenates on day 21 after
intratracheal instillation of PPE or saline. Data represent the mean ± SEM (n=8 in each group).
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the airways [18-20,36] and peripheral blood [37] of
COPD patients have been reported to be increased.
These studies suggested an association between Th17
and COPD, however, the role for IL-17A in disease de-
velopment is not defined.
In the present study, to elucidate the role of IL-17A in
the development of emphysema, we investigated PPE-
induced initial inflammation and subsequent late phase
emphysematous change in IL-17A−/− and WT mice.
We demonstrated that both the PPE-induced acute
phase inflammation and the late phase emphysematous
changes seen in WT mice were attenuated in IL-17A−/−
mice. Increased levels of neutrophil-related chemokines
such as KC, MIP-2 and IL-1β seen in the BAL fluid of
WT mice were also significantly reduced in IL-17A−/−mice following PPE administration. These data, for the
first time, indicated that IL-17A may play a role in the
elastase-induced pulmonary pathology.
We observed that levels of IL-17A in the lungs were
increased in the acute phase following PPE treatment. The
numbers of IL-17A producing cells in the lung were also
increased following PPE treatment. Thus, elastase admin-
istration leads to increases in both IL-17-producing cells
and levels of IL-17A. These results were consistent with
the observations showing that IL-17A expressing cells
were increased in the airways of COPD patients. For ex-
ample, numbers of IL-17A+ cells in the bronchial sub-
mucosa were increased in COPD compared to smokers
without COPD and nonsmoking control subjects [19].
The sputum concentrations of IL-17A in COPD were
increased compared to patients with asthma [19]. It has
Figure 5 IL-17A levels in the lung. IL-17A levels in lung
homogenates of WT mice after intratracheal instillation of PPE were
measured by ELISA as described in Methods. The results for each
group are expressed as means ± SEM (n=8 in each group). *p <0.01,
day 0 and day 0.5 versus day 1 and day 2.
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juvant effect on CD4 T cell activation and differentiation
to Th17 cells in vitro [38]. These data suggest that smok-
ing induces both IL-17A secretion in the airways and
increases differentiation of Th17 cells.
IL-17A has been shown to accumulate [39] and acti-
vate neutrophils [40], and enhance epithelial production
of IL-8 [41]. It has also been reported that IL-17A acts
directly on epithelial cells, airway fibroblasts and smooth
muscle cells to induce the secretion of neutrophil-
recruiting chemokines [42]. Airway smooth muscle
strips from COPD patients expressed IL-17RA and
responded to IL-17A by inducing IL-8 production [16].
Rodents lack a direct homologue of IL-8, but the chemo-
kines KC and MIP-2 are regarded as functional homolo-
gues and have been found to contribute to the pathology
of a number of neutrophil-dependent animal models of
disease [43]. In the present study, levels of KC and MIP-
2 were increased in WT mice following PPE treatment,
and these levels were lower in IL-17A−/− mice. Thus
IL-17A may induce neutrophil chemotactic factor pro-
duction, KC and MIP-2, and contribute to neutrophilic
airway inflammation following PPE treatment.
Th17 cells have been shown to produce more inflam-
matory cytokines, such as IL-1β, compared with regula-
tory T cells and other T-helper cells [44]. In the present
study, the levels of IL-1β in WT mice were increased
4 days after intratracheal PPE instillation and levels were
significantly lower in IL-17A−/− mice. Although the link
between acute inflammatory changes and the subsequent
development of emphysematous changes requires furtherinvestigation, it is likely that in addition to KC and MIP-2,
increased levels of proinflammatory cytokines such as
IL-1β prolong and enhance acute inflammation and
contribute to later emphysema. In this way, IL-17A-
mediated pathways might play a central role in the
pathophysiological events.
Chen et al. recently reported that IL-17RA-deficient mice
failed to develop emphysema after 6 months of cigarette
smoke exposure in contrast to wild-type mice [38]. In their
study, the wild-type mice which received 6 months smok-
ing exposure showed higher levels of IL-17 in BAL
fluid compared to sham-exposed mice. IL-17RA−/−
mice showed lower levels of monocyte chemotactic
protein-1 (MCP-1) in BAL fluid and lower expression
of the matrix metalloproteinase (MMP)-9 and MMP-12 in
the lung, compared to wild-type mice, suggesting an im-
portant role for IL-17RA in macrophage recruitment to
the inflamed lung and for development of emphysema.
They saw no differences in KC levels in BAL fluid between
IL-17RA−/− mice and wild-type mice when emphysema
was established, similar to our study. In the present study,
however, we have shown that neutrophil-related chemo-
kines such as KC and MIP-2 were increased at a relatively
early stage following elastase treatment, which was asso-
ciated with increased levels of IL-17A, and increased
numbers of neutrophils in the airways, suggesting an im-
portant role for IL-17A in the recruitment of neutrophils
at a relatively early stage. IL-17RA has at least three
ligands including IL-17A, IL-17 F, and IL-25. In the
present study, we demonstrated the importance of IL-17A
for emphysema using IL-17A−/− mice. Shan et al. have
also shown that cigarette smoke-induced emphysema is
mediated by IL-17A in mice [45]. Regarding other ligands
for IL17RA, IL-25 has been reported to be associated with
both Th2 and Th17 immune responses [46], however, little
is known about the role of this cytokine in emphysema de-
velopment. Expression of both IL-17A and IL-17 F were
increased in the airways of COPD subjects in both inflam-
matory cells as well as in the airway epithelium [18,19]. In
contrast, numbers of IL-17 F+ cells were not increased in
COPD compared to control subjects [20].
In the present study, elastase-induced emphysematous
changes of the lung in IL-17A−/− mice were reduced,
but not completely attenuated compared to WT mice,
suggesting that IL-17A may be essential but not suffi-
cient for the full development of elastase-induced em-
physema. Previous studies have shown that Th1 cells
contribute largely to the inflammatory cascade of events
related to the pathogenesis of COPD [34,35]. It has also
been reported that Th2 cells may be important in the in-
flammatory response of the disease [47-49]. Using IL-18
transgenic mice with disruption of the IL-13 gene,
Hoshino et al. have shown that IL-18 and IL-13 might
have important roles in the pathogenesis of emphysema
Figure 6 Intracellular detection of IL-17A and IFN-γ in lung CD4+ T cells from WT mice 2 days after elastase administration. (A)
Percentages of IL-17A+ and IFN-γ+ T cells following saline treatment (Saline group) or PPE treatment (PPE group). Intracellular IL-17A and IFN-γ
were assessed as described in Methods. The data shown are representative of two independent experiments. (B) The numbers of IL-17A+ and
IFN-γ+ CD4 T cells in the lung of WT mice. The numbers of IL-17A+ CD4 T cells and IFN-γ+ CD4 T cells were calculated as described in Methods.
Groups are the same as in (A). Data represent the mean ± SEM (n=6 in each group). *p<0.05 versus saline-treated group.
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sion of IL-18 induced emphysema via IFN-γ and IL-17A,
and induced mucus metaplasia via IL-13 [51]. Chronic
cigarette smoke has been shown to induce both Th1 and
Th17 cells in mice [52]. Thus, although Th17 cells may
play an important role in the pathogenesis of emphy-
sema, their role is not exclusive and Th1 and Th2 cells
may also have contributory roles. Further understanding
of how these helper T cell subsets interact and orches-
trate a pathological response to smoking will be essential
if we are to successfully intervene in the development
and progression of COPD and emphysema.Conclusions
We demonstrated that IL-17A plays an important role
to the development of PPE-induced acute phase neutro-
philic inflammation and subsequent emphysematous
change of the lung, which was associated with increased
levels of neutrophil-related chemokines such as KC,
MIP-2 and IL-1β. Numbers of Th17 cells as well as IL-
17A levels in the lung were increased following treatment
with elastase. Our data suggest that targeting IL-17A in
emphysema may be a hopeful therapeutic strategy for
improving clinical outcomes and for delaying disease pro-
gression (Additional file 1).
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Additional file 1: Figure S1. Cellular composition in BAL fluid on
day 2 after intratracheal instillation of PPE or saline. *p<0.05
compared to WT saline and IL-17A-/- saline. #p<0.05 versus WT PPE. n=8
in each group.
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